Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Verma S, et al. Circulation. 2021 Dec 7;144(23):1845-1855. doi: 10.1161/CIRCULATIONAHA.121.056290. Epub 2021 Oct 28. Circulation. 2021. PMID: 34710343 Free article. Clinical Trial.
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.
Stein EM, de Botton S, Cluzeau T, Pigneux A, Liesveld JL, Cook RJ, Rousselot P, Rizzieri DA, Braun T, Roboz GJ, Lebon D, Heiblig M, Baker K, Volkert A, Paul S, Rajagopal N, Roth DA, Kelly M, Peterlin P. Stein EM, et al. Among authors: roth da. Leuk Lymphoma. 2023 Dec;64(12):1992-2001. doi: 10.1080/10428194.2023.2243356. Epub 2023 Aug 12. Leuk Lymphoma. 2023. PMID: 37571998
Contaminant Exposure and Transport from Three Potential Reuse Waters within a Single Watershed.
Masoner JR, Kolpin DW, Cozzarelli IM, Bradley PM, Arnall BB, Forshay KJ, Gray JL, Groves JF, Hladik ML, Hubbard LE, Iwanowicz LR, Jaeschke JB, Lane RF, McCleskey RB, Polite BF, Roth DA, Pettijohn MB, Wilson MC. Masoner JR, et al. Among authors: roth da. Environ Sci Technol. 2023 Jan 10;57(3):1353-65. doi: 10.1021/acs.est.2c07372. Online ahead of print. Environ Sci Technol. 2023. PMID: 36626647 Free PMC article.
Bottled water contaminant exposures and potential human effects.
Bradley PM, Romanok KM, Smalling KL, Focazio MJ, Evans N, Fitzpatrick SC, Givens CE, Gordon SE, Gray JL, Green EM, Griffin DW, Hladik ML, Kanagy LK, Lisle JT, Loftin KA, Blaine McCleskey R, Medlock-Kakaley EK, Navas-Acien A, Roth DA, South P, Weis CP. Bradley PM, et al. Among authors: roth da. Environ Int. 2023 Jan;171:107701. doi: 10.1016/j.envint.2022.107701. Epub 2022 Dec 15. Environ Int. 2023. PMID: 36542998 Free PMC article.
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
de Botton S, Cluzeau T, Vigil C, Cook RJ, Rousselot P, Rizzieri DA, Liesveld JL, Fenaux P, Braun T, Banos A, Jurcic JG, Sekeres MA, Savona MR, Roboz GJ, Bixby D, Madigan K, Volkert A, Stephens K, Kang-Fortner Q, Baker K, Paul S, McKeown M, Carulli J, Eaton M, Hodgson G, Fiore C, Kelly MJ, Roth DA, Stein EM. de Botton S, et al. Among authors: roth da. Blood Adv. 2023 May 9;7(9):1858-1870. doi: 10.1182/bloodadvances.2022008806. Blood Adv. 2023. PMID: 36477975 Free PMC article.
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome.
Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, Gardner DH, Henderson RB, Herdman M, Lerang K, Mistry P, Punwaney R, Seror R, Stone J, van Daele P, van Maurik A, Wisniacki N, Roth DA, Tak PP. Mariette X, et al. Among authors: roth da. JCI Insight. 2022 Dec 8;7(23):e163030. doi: 10.1172/jci.insight.163030. JCI Insight. 2022. PMID: 36477362 Free PMC article. Clinical Trial.
188 results